Company news

AbCellera Biologics Inc. news in 2022

AbCellera Biologics Inc.'s news releases, calls and decks from 2022, newest first.

View company

AbCellera and AbbVie Partner to Advance New Antibody Therapies

December 14, 2022

AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases

November 30, 2022

AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022

November 9, 2022

AbCellera Reports Q3 2022 Business Results

November 7, 2022

AbCellera to Present at Upcoming Investor Conferences in November

November 3, 2022

AbCellera’s First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development

November 1, 2022

AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022

October 10, 2022

AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022

October 4, 2022

AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic

September 20, 2022

AbCellera Reports Q2 2022 Business Results

August 8, 2022

AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients

August 2, 2022

AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022

July 11, 2022

Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options

June 28, 2022

AbCellera Reports Q1 2022 Business Results

May 9, 2022

AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration

May 2, 2022

AbCellera to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022

April 25, 2022

AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022

April 11, 2022

AbCellera Presents Data on T Cell Engager Platform at AACR 2022

April 7, 2022

AbCellera Reports Full Year 2021 Business Results

February 23, 2022

AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools

February 22, 2022

AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022

February 10, 2022

AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19

February 10, 2022

AbCellera to Report Full Year 2021 Financial Results on February 24, 2022

January 26, 2022

Calls in 2022

Decks in 2022